Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

GSK and other Olympic sponsors may face hacking attack

IT security firm claims ‘hacktivist’ network Anonymous could target websites of London 2012 partners

GlaxoSmithKline could be targeted by 'hacktivist' network Anonymous, according to reports.

IT security firm Radware claims to have found evidence the hacking network, which earlier this year took down several UK government sites, is preparing to launch a denial-of-service attack on the pharma company's website.

Carl Herberger, vice president of security solutions at Radware, told Network World US that online posts indicate Anonymous could attack GSK and telecoms firm BT, both of whom are prominent sponsors of the London 2012 Games.

While there is, as expected, no way of verifying the information, which comes from someone claiming links with Anonymous, Herberger said some previous attacks have followed a similar pattern.

The potential threat emerged just over a year Bayer's Italian website was hit by 'illegal interference' by hackers affiliated with Anonymous in June, 2011.

Meanwhile, a separate UK group called The Script Kiddies took over Pfizer's Facebook page last July, defacing it and adding links to several articles critical of the pharma company.

1st August 2012

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...